Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: Focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Syggelos, Spyros A ^a   Aletras, Alexios J ^b   Smirlaki, Ioanna ^b   Skandalis, Spyros S ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; CYCLOOXYGENASE 2; FIBRONECTIN; GELATINASE A; GELATINASE B; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 15; MATRIX METALLOPROTEINASE 16; MATRIX METALLOPROTEINASE 26; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL COLLAGENASE; PROTEASOME; PROTEASOME INHIBITOR; SCAVENGER RECEPTOR; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSCRIPTION FACTOR AP 1;

ANTIGEN PRESENTATION; CONNECTIVE TISSUE; CYTOKINE RELEASE; ENZYMATIC DEGRADATION; EXTRACELLULAR MATRIX; HUMAN; IMMUNOHISTOCHEMISTRY; JOINT PROSTHESIS; MACROPHAGE; MICROENVIRONMENT; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHAGOCYTOSIS; PROSTHESIS LOOSENING; PROTEIN BLOOD LEVEL; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; ENZYMOLOGY; METABOLISM; PROSTHESIS FAILURE; ETIOLOGY; THERAPY;

EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; OSTEOLYSIS; PROSTHESIS FAILURE; PROTEASOME ENDOPEPTIDASE COMPLEX; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84880159475     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/230805     Document Type: Review

References (178)

1. Sundfeldt M., Carlsson L. V., Johansson C. B., Thomsen P., Gretzer C., Aseptic loosening, not only a question of wear: a review of different theories. Acta Orthopaedica 2006 77 2 177 197 2-s2.0-33645776769 10.1080/17453670610045902
2. Dumbleton J. H., Manley M. T., Edidin A. A., A literature review of the association between wear rate and osteolysis in total hip arthroplasty. Journal of Arthroplasty 2002 17 5 649 661 2-s2.0-0036023527 10.1054/arth.2002.33664
3. Schmalzried T. P., Jasty M., Harris W. H., Periprosthetic bone loss in total hip arthroplasty. Polyethylene wear debris and the concept of the effective joint space. Journal of Bone and Joint Surgery A 1992 74 6 849 863 2-s2.0-0026662669
4. Hirakawa K., Bauer T. W., Stulberg B. N., Comparison and quantitation of wear debris of failed total hip and total knee arthroplasty. Journal of Biomedical Materials Research 1996 31 257 263
5. Margevicius K. J., Bauer T. W., McMahon J. T., Brown S. A., Merritt K., Isolation and characterization of debris in membranes around total joint prostheses. Journal of Bone and Joint Surgery A 1994 76 11 1664 1675 2-s2.0-0028076951
6. Schwarz E. M., Benz E. B., Lu A. P., Goater J. J., Mollano A. V., Rosier R. N., Puzas J. E., O'Keefe R. J., Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. Journal of Orthopaedic Research 2000 18 6 849 855 2-s2.0-0034319201 10.1002/jor.1100180602
7. Millett P. J., Allen M. J., Bostrom M. P. G., Effects of alendronate on particle-induced osteolysis in a rat model. Journal of Bone and Joint Surgery A 2002 84 2 236 249 2-s2.0-0036481537
8. Merkel K. D., Erdmann J. M., McHugh K. P., Abu-Amer Y., Ross F. P., Teitelbaum S. L., Tumor necrosis factor- α mediates orthopedic implant osteolysis. American Journal of Pathology 1999 154 1 203 210 2-s2.0-0032893277
9. Shanbhag A. S., Hasselman C. T., Rubash H. E., The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clinical Orthopaedics and Related Research 1997 344 33 43 2-s2.0-0031280306
10. Wooley P. H., Morren R., Andary J., Sud S., Yang S.-Y., Mayton L., Markel D., Sieving A., Nasser S., Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials 2002 23 2 517 526 2-s2.0-0036131537 10.1016/S0142-9612(01)00134-X
11. Warme B. A., Epstein N. J., Trindade M. C. D., Miyanishi K., Ma T., Saket R. R., Regula D., Goodman S. B., Smith R. L., Proinflammatory mediator expression in a novel murine model of titanium-particle-induced intramedullary inflammation. Journal of Biomedical Materials Research B 2004 71 2 360 366 2-s2.0-7744224782 10.1002/jbm.b.30120
12. Yang S.-Y., Wu B., Mayton L., Mukherjee P., Robbins P. D., Evans C. H., Wooley P. H., Protective effects of IL-1Ra or vIL-10 gene transfer on a murine model of wear debris-induced osteolysis. Gene Therapy 2004 11 5 483 491 2-s2.0-1542329568 10.1038/sj.gt.3302192
13. Blaine T. A., Rosier R. N., Puzas J. E., Looney R. J., Reynolds P. R., Reynolds S. D., O'Keefe R. J., Increased levels of tumor necrosis factor- α and interleukin-6 protein and messenger RNA in human peripheral blood monocytes due to titanium particles. Journal of Bone and Joint Surgery A 1996 78 8 1181 1192 2-s2.0-0029792399
14. Nakashima Y., Sun D.-H., Trindade M. C. D., Maloney W. J., Goodman S. B., Schurman D. J., Smith L. R., Signaling pathways for tumor necrosis factor- α and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. Journal of Bone and Joint Surgery A 1999 81 5 603 615 2-s2.0-0032971714
15. Wimhurst J. A., Brooks R. A., Rushton N., Inflammatory responses of human primary macrophages to particulate bone cements in vitro. Journal of Bone and Joint Surgery B 2001 83 2 278 282 2-s2.0-0035083309
16. Ingham E., Green T. R., Stone M. H., Kowalski R., Watkins N., Fisher J., Production of TNF- α and bone resorbing activity by macrophages in response to different types of bone cement particles. Biomaterials 2000 21 10 1005 1013 2-s2.0-0034017552 10.1016/S0142-9612(99)00261-6
17. Maloney W. J., James R. E., Smith R. L., Human macrophage response to retrieved titanium alloy particles in vitro. Clinical Orthopaedics and Related Research 1996 322 268 278 2-s2.0-0030064233
18. Saleh K. J., Thongtrangan I., Schwarz E. M., Osteolysis: medical and surgical approaches. Clinical Orthopaedics and Related Research 2004 427 138 147 2-s2.0-5444220270 10.1097/01.blo.0000142288.66246.4d
19. Purdue P. E., Koulouvaris P., Nestor B. J., Sculco T. P., The central role of wear debris in periprosthetic osteolysis. HSS Journal 2006 2 2 102 113 2-s2.0-33748291470 10.1007/s11420-006-9003-6
20. Schmalzried T. P., Jasty M., Harris W. H., Periprosthetic bone loss in total hip arthroplasty. Polyethylene wear debris and the concept of the effective joint space. Journal of Bone and Joint Surgery A 1992 74 6 849 863 2-s2.0-0026662669
21. Glant T. T., Jacobs J. J., Molnar G., Shanbhag A. S., Valyon M., Galante J. O., Bone resorption activity of particulate-stimulated macrophages. Journal of Bone and Mineral Research 1993 8 9 1071 1079 2-s2.0-0027304584
22. Goppelt-Struebe M., Stroebel M., Synergistic induction of monocyte chemoattractant protein-1 (MCP-1) by platelet-derived growth factor and interleukin-1. FEBS Letters 1995 374 3 375 378 2-s2.0-0028804137 10.1016/0014-5793(95)01155-8
23. Horowitz S. M., Gonzales J. B., Inflammatory response to implant particulates in a macrophage/osteoblast coculture model. Calcified Tissue International 1996 59 5 392 396 2-s2.0-0029864496 10.1007/s002239900145
24. Ishiguro N., Kojima T., Ito T., Saga S., Anma H., Kurokonchi K., Iwahori Y., Iwase T., Iwata H., Macrophage activation and migration in interface tissue around loosening total hip arthro plasty components. Journal of Biomedical Materials Research 1997 35 399 406
25. Kadoya Y., Revell P. A., Al-Saffar N., Kobayashi A., Scott G., Freeman M. A. R., Bone formation and bone resorption in failed total joint arthroplasties: histomorphometric analysis with histochemical and immunohistochemical technique. Journal of Orthopaedic Research 1996 14 3 473 482 2-s2.0-0030152803 10.1002/jor.1100140318
26. Pizzoferrato A., Stea S., Sudanese A., Toni A., Nigrisoli M., Gualtieri G., Squarzoni S., Morphometric and microanalytical analyses of alumina wear particles in hip prostheses. Biomaterials 1993 14 8 583 587 2-s2.0-0027626613 10.1016/0142-9612(93)90175-2
27. DeHeer D. H., Engels J. A., DeVries A. S., In situ complement activation by polyethylene wear debris. Journal of Biomedical Materials Research 2001 54 12 19
28. Santavirta S., Hoikka V., Eskola A., Konttinen Y. T., Paavilainen T., Tallroth K., Aggressive granulomatous lesions in cementless total hip arthroplasty. Journal of Bone and Joint Surgery B 1990 72 6 980 984 2-s2.0-0025107603
29. Rezzonico R., Chicheportiche R., Imbert V., Dayer J.-M., Engagement of CD11b and CD11c β 2 integrin by antibodies or soluble CD23 induces IL-1 β production on primary human monocytes through mitogen- activated protein kinase-dependent pathways. Blood 2000 95 12 3868 3877 2-s2.0-0034660486
30. Rezzonico R., Imbert V., Chicheportiche R., Dayer J.-M., Ligation of CD11b and CD11c β 2 integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1 α (MIP-1 α) and MIP-1 β production in primary human monocytes through a pathway dependent on nuclear factor- B. Blood 2001 97 10 2932 2940 2-s2.0-0035874494 10.1182/blood.V97.10. 2932
31. Palecanda A., Paulauskis J., Al-Mutairi E., Imrich A., Qin G., Suzuki H., Kodama T., Tryggvason K., Koziel H., Kobzik L., Role of the scavenger receptor MARCO in alveolar macrophage binding of unopsonized environmental particles. The Journal of Experimental Medicine 1999 189 9 1497 1506 2-s2.0-0033519286 10.1084/jem.189.9.1497
32. Rakshit D. S., Lim J. T. E., Ly K., Ivashkiv L. B., Nestor B. J., Sculco T. P., Purdue P. E., Involvement of complement receptor 3 (CR3) and scavenger receptor in macrophage responses to wear debris. Journal of Orthopaedic Research 2006 24 11 2036 2044 2-s2.0-33750892425 10.1002/jor.20275
33. Sun D.-H., Trindade M. C. D., Nakashima Y., Maloney W. J., Goodman S. B., Schurman D. J., Smith R. L., Human serum opsonization of orthopedic biomaterial particles: protein-binding and monocyte/macrophage activation in vitro. Journal of Biomedical Materials Research A 2003 65 2 290 298 2-s2.0-0346851949
34. Horiki M., Nakase T., Myoui A., Sugano N., Nishii T., Tomita T., Miyaji T., Yoshikawa H., Localization of RANKL in osteolytic tissue around a loosened joint prosthesis. Journal of Bone and Mineral Metabolism 2004 22 4 346 351 2-s2.0-3242787387
35. Quinn J. M. W., Horwood N. J., Elliott J., Gillespie M. T., Martin T. J., Fibroblastic stromal cells express receptor activator of NF- B ligand and support osteoclast differentiation. Journal of Bone and Mineral Research 2000 15 8 1459 1466 2-s2.0-0033914968
36. Yao J., Glant T. T., Lark M. W., Mikecz K., Jacobs J. J., Hutchinson N. I., Hoerrner L. A., Kuettner K. E., Galante J. O., The potential role of fibroblasts in periprosthetic osteolysis: fibroblast response to titanium particles. Journal of Bone and Mineral Research 1995 10 9 1417 1427 2-s2.0-0029153594
37. Manlapaz M., Maloney W. J., Smith R. L., In vitro activation of human fibroblasts by retrieved titanium alloy wear debris. Journal of Orthopaedic Research 1996 14 3 465 472 2-s2.0-0030152361 10.1002/jor.1100140317
38. Vermes C., Chandrasekaran R., Jacobs J. J., Galante J. O., Roebuck K. A., Glant T. T., The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. Journal of Bone and Joint Surgery A 2001 83 2 201 211 2-s2.0-0035110245
39. Lochner K., Fritsche A., Jonitz A., Hansmann D., Mueller P., Mueller-Hilke B., Bader R., The potential role of human osteoblasts for periprosthetic osteolysis following exposure to wear particles. International Journal of Molecular Medicine 2011 28 6 1055 1063 2-s2.0-80053549892 10.3892/ijmm.2011.778
40. Sabokbar A., Kudo O., Athanasou N. A., Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. Journal of Orthopaedic Research 2003 21 1 73 80 2-s2.0-0037260653 10.1016/S0736-0266(02)00106-7
41. Wang C.-T., Lin Y.-T., Chiang B.-L., Lee S.-S., Hou S.-M., Over-expression of receptor activator of nuclear factor- B ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty. Biomaterials 2010 31 1 77 82 2-s2.0-70350342858 10.1016/j.biomaterials.2009.09.017
42. Möller B., Villiger P. M., Inhibition of IL-1, IL-6, and TNF- α in immune-mediated inflammatory diseases. Springer Seminars in Immunopathology 2006 27 4 391 408 2-s2.0-33744719480 10.1007/s00281-006-0012-9
43. Horai R., Saijo S., Tanioka H., Nakae S., Sudo K., Okahara A., Ikuse T., Asano M., Iwakura Y., Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin I receptor antagonist-deficient mice. The Journal of Experimental Medicine 2000 191 2 313 320 2-s2.0-0034677123 10.1084/jem.191.2.313
44. Caicedo M., Jacobs J. J., Hallab N. J., Inflammatory bone loss in joint replacements: the mechanisms. Journal Musculoskeletal Medicine 2010 27 209 216
45. Lerner U. H., Ohlin A., Tumor necrosis factors α and β can stimulate bone resorption in cultured mouse calvariae by a prostaglandin- independent mechanism. Journal of Bone and Mineral Research 1993 8 2 147 155 2-s2.0-0027512024
46. Horowitz S. M., Purdon M. A., Mediator interactions in macrophage/particulate bone resorption. Journal of Biomedical Materials Research 1995 29 4 477 484 2-s2.0-0029278186 10.1002/jbm.820290407
47. Chiba J., Rubash H. E., Kim K. J., Iwaki Y., The characterization of cytokines in the interface tissue obtained from failed cementless total hip arthroplasty with and without femoral osteolysis. Clinical Orthopaedics and Related Research 1994 300 304 312 2-s2.0-0028267024
48. Takei H., Pioletti D., Kwon S. Y., Sung P., Combined effect of titanium particles and TNF-a on the production of IL-6 by osteoblast-like cells. Journal of Biomedical Materials Research 2000 52 382 387
49. Gowen M., Wood D. D., Ihrie E. J., McGuire M. K., Russell R. G., An interleukin 1 like factor stimulates bone resorption in vitro. Nature 1983 306 5941 378 380 2-s2.0-0021069905
50. Akatsu T., Takahashi N., Udagawa N., Imamura K., Yamaguchi A., Sato K., Nagata N., Suda T., Role of prostaglandins in interleukin-1-induced bone resorption in mice in vitro. Journal of Bone and Mineral Research 1991 6 2 183 190 2-s2.0-0026061080
51. Goodman S. B., Chin R. C., Chiou S. S., Schurman D. J., Woolson S. T., Masada M. P., A clinical-pathologic-biochemical study of the membrane surrounding loosened and nonloosened total hip arthroplasties. Clinical Orthopaedics and Related Research 1989 244 182 187 2-s2.0-0024387082
52. Jiranek W. A., Machado M., Jasty M., Jevsevar D., Wolfe H. J., Goldring S. R., Goldberg M. J., Harris W. H., Production of cytokines around loosened cemented acetabular components: analysis with immunohistochemical techniques and in situ hybridization. Journal of Bone and Joint Surgery A 1993 75 6 863 879 2-s2.0-0027326202
53. Kusano K., Miyaura C., Inada M., Tamura T., Ito A., Nagase H., Kamoi K., Suda T., Regulation of matrix metalloproteinases (MMP-2,-3,-9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998 139 3 1338 1345 2-s2.0-0031738172 10.1210/en.139.3.1338
54. Ishimi Y., Miyaura C., Jin C. H., Akatsu T., Abe E., Nakamura Y., Yamaguchi A., Yoshiki S., Matsuda T., Hirano T., Kishimoto T., Suda T., IL-6 is produced by osteoblasts and induces bone resorption. Journal of Immunology 1990 145 10 3297 3303 2-s2.0-0025259989
55. Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G. D., IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. Journal of Immunology 1990 144 11 4226 4230 2-s2.0-0025313227
56. Goldring S. R., Jasty M., Roelke M. S., Rourke C. M., Bringhurst F. R., Harris W. H., Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement. Arthritis and Rheumatism 1986 29 7 836 842 2-s2.0-0022510812
57. Appel A. M., Sowder W. G., Siverhus S. W., Hopson C. N., Herman J. H., Prosthesis-associated pseudomembrane-induced bone resorption. British Journal of Rheumatology 1990 29 1 32 36 2-s2.0-0025190684
58. Takagi M., Konttinen Y. T., Santavirta S., Sorsa T., Eisen A. Z., Nordsletten L., Suda A., Extracellular matrix metalloproteinases around loose total hip prostheses. Acta Orthopaedica Scandinavica 1994 65 3 281 286 2-s2.0-0028246414
59. Fritz E. A., Glant T. T., Vermes C., Jacobs J. J., Roebuck K. A., Chemokine gene activation in human bone marrow-derived osteoblasts following exposure to particulate wear debris. Journal of Biomedical Materials Research A 2006 77 1 192 201 2-s2.0-33645939840 10.1002/jbm.a.30609
60. Huang Z., Ma T., Ren P.-G., Smith R. L., Goodman S. B., Effects of orthopedic polymer particles on chemotaxis of macrophages and mesenchymal stem cells. Journal of Biomedical Materials Research A 2010 94 4 1264 1269 2-s2.0-77956453902 10.1002/jbm.a.32803
61. Goodman S. B., Ma T., Cellular chemotaxis induced by wear particles from joint replacements. Biomaterials 2010 31 19 5045 5050 2-s2.0-77952289075 10.1016/j.biomaterials.2010.03.046
62. Hukkanen M., Corbett S. A., Batten J., Konttinen Y. T., McCarthy I. D., Maclouf J., Santavirta S., Hughes S. P. F., Polak J. M., Aseptic loosening of total hip replacement. Macrophage expression of inducible nitric oxide synthase and cyclo-oxygenase-2, together with peroxynitrite formation, as a possible mechanism for early prosthesis failure. Journal of Bone and Joint Surgery B 1997 79 3 467 474 2-s2.0-0030943994 10.1302/0301-620X.79B3.7469
63. Harris S. G., Padilla J., Koumas L., Ray D., Phipps R. P., Prostaglandins as modulators of immunity. Trends in Immunology 2002 23 3 144 150 2-s2.0-0036499224 10.1016/S1471-4906(01)02154-8
64. Steeve K. T., Marc P., Sandrine T., Dominique H., Yannick F., IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine and Growth Factor Reviews 2004 15 1 49 60 2-s2.0-1642432081 10.1016/j.cytogfr.2003.10.005
65. Nagase H., Visse R., Murphy G., Structure and function of matrix metalloproteinases and TIMPs. Cardiovascular Research 2006 69 3 562 573 2-s2.0-31344458952 10.1016/j.cardiores.2005.12.002
66. Leco K. J., Waterhouse P., Sanchez O. H., Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). The Journal of Clinical Investigation 2001 108 817 829
67. Fata J. E., Leco K. J., Voura E. B., Yu H.-Y. E., Waterhouse P., Murphy G., Moorehead R. A., Khokha R., Accelerated apoptosis in the Timp-3-deficient mammary gland. The Journal of Clinical Investigation 2001 108 6 831 841 2-s2.0-0034823461 10.1172/JCI200113171
68. English J. L., Kassiri Z., Koskivirta I., Atkinson S. J., Di Grappa M., Soloway P. D., Nagase H., Vuorio E., Murphy G., Khokha R., Individual Timp deficiencies differentially impact pro-MMP-2 activation. The Journal of Biological Chemistry 2006 281 15 10337 10346 2-s2.0-33744542903 10.1074/jbc.M512009200
69. Ray J. M., Stetler-Stevenson W. G., The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. European Respiratory Journal 1994 7 11 2062 2072 2-s2.0-0028073883
70. Takei I., Takagi M., Santavirta S., Ida H., Ishii M., Ogino T., Ainola M., Konttinen Y. T., Messenger ribonucleic acid expression of 16 matrix metalloproteinases in bone-implant interface tissues of loose artificial hip joints. Journal of Biomedical Materials Research 2000 52 613 620
71. Sasaki K., Takagi M., Mandelin J., Takei I., Santavirta S., Ida H., Ogino T., Konttinen Y. T., Quantitative analysis of mRNA expression of TIMPs in the periprosthetic interface tissue of loose hips by real-time PCR system. Journal of Biomedical Materials Research 2001 58 6 605 612 2-s2.0-0035191825 10.1002/jbm.1059
72. Li T.-F., Santavirta S., Virtanen I., Könönen M., Takagi M., Konttinen Y. T., Increased expression of EMMPRIN in the tissue around loosened hip prostheses. Acta Orthopaedica Scandinavica 1999 70 5 446 451 2-s2.0-0032741554
73. Nawrocki B., Polette M., Burlet H., Birembaut P., Adnet J.-J., Expression of gelatinase A and its activator MT1-MMP in the inflammatory periprosthetic response to polyethylene. Journal of Bone and Mineral Research 1999 14 2 288 294 2-s2.0-0032928062 10.1359/jbmr.1999.14.2.288
74. Hembry R. M., Bagga M. R., Reynolds J. J., Hamblen D. L., Stromelysin, gelatinase A and TIMP-1 in prosthetic interface tissue: a role for macrophages in tissue remodelling. Histopathology 1995 27 2 149 159 2-s2.0-0029086812
75. Takagi M., Neutral proteinases and their inhibitors in the loosening of total hip prostheses. Acta orthopaedica Scandinavica. Supplementum 1996 271 3 29 2-s2.0-34247613912
76. Yokohama Y., Matsumoto T., Hirakawa M., Kuroki Y., Fujimoto N., Imai K., Okada Y., Production of matrix metalloproteinases at the bone-implant interface in loose total hip replacements. Laboratory Investigation 1995 73 6 899 911 2-s2.0-0029562999
77. Takagi M., Konttinen Y. T., Lindy O., Sorsa T., Kurvinen H., Suda A., Santavirta S., Gelatinase/Type IV collagenases in the loosening of total hip replacement endoprostheses. Clinical Orthopaedics and Related Research 1994 306 136 144 2-s2.0-0028034460
78. Takagi M., Konttinen Y. T., Kemppinen P., Sorsa T., Tschesche H., Blaser J., Suda A., Santavirta S., Tissue inhibitor of metalloproteinase 1, collagenolytic and gelatinolytic activity in loose hip endoprostheses. Journal of Rheumatology 1995 22 12 2285 2290 2-s2.0-0028828660
79. Santavirta S., Takagi M., Konttinen Y. T., Sorsa T., Suda A., Inhibitory effect of cephalothin on matrix metalloproteinase activity around loose hip prostheses. Antimicrobial Agents and Chemotherapy 1996 40 1 244 246 2-s2.0-0030030892
80. Ishiguro N., Ito T., Kurokouchi K., Iwahori Y., Nagaya I., Hasegawa Y., Iwata H., mRNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in interface tissue around implants in loosening total hip arthroplasty. Journal of Biomedical Materials Research 1996 32 611 617
81. Strongin A. Y., Collier I., Bannikov G., Marmer B. L., Grant G. A., Goldberg G. I., Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. The Journal of Biological Chemistry 1995 270 10 5331 5338 2-s2.0-0028907318 10.1074/jbc.270.10.5331
82. Syggelos S. A., Eleftheriou S. C., Giannopoulou E., Panagiotopoulos E., Aletras A. J., Gelatinolytic and collagenolytic activity in periprosthetic tissues from loose hip endoprostheses. Journal of Rheumatology 2001 28 6 1319 1329 2-s2.0-0034991296
83. Goldberg G. I., Wilhelm S. M., Kronberger A., Bauer E. A., Grant G. A., Eisen A. Z., Human fibroblast collagenase. The Journal of Biological Chemistry 1986 261 6600 6605
84. Hasty K. A., Jeffrey J. J., Hibbs M. S., Welgus H. G., The collagen substrate specificity of human neutrophil collagenase. The Journal of Biological Chemistry 1987 262 21 10048 10052 2-s2.0-0023202438
85. Chambers T. J., Darby J. A., Fuller K., Mammalian collagenase predisposes bone surfaces to osteoclastic resorption. Cell and Tissue Research 1985 241 3 671 675 2-s2.0-0022259759
86. Nordsletten L., Buø L., Takagi M., Konttinen Y. T., Yamakawa M., Santavirta S., Aasen A. O., The plasminogen activation system is upregulated in loosening of total hip prostheses. Acta Orthopaedica Scandinavica 1996 67 2 143 148 2-s2.0-0029935660
87. Kazes I., Delarue F., Hagège J., Bouzhir-sima L., Rondeau E., Sraer J.-D., Nguyen G., Soluble latent membrane-type 1 matrix metalloprotease secreted by human mesangial cells is activated by urokinase. Kidney International 1998 54 6 1976 1984 2-s2.0-0031756112 10.1046/j.1523-1755.1998. 00216.x
88. Carmeliet P., Moons L., Lijnen R., Baes M., Lema tre V., Tipping P., Drew A., Eeckhout Y., Shapiro S., Lupu F., Collen D., Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nature Genetics 1997 17 4 439 444 2-s2.0-16944363984
89. Diehl P., Hantke B., Hennig M., Tschesche H., Mittelmeier W., Schmitt M., Muehlenweg B., Protein expression of MMP-13, uPA, and PAI-1 in pseudocapsular and interface tissue around implants of loose artificial hip joints and in osteoarthritis. International Journal of Molecular Medicine 2004 13 5 711 715 2-s2.0-16644397248
90. Nakashima Y., Sun D.-H., Maloney W. J., Goodman S. B., Schurman D. J., Smith R. L., Induction of matrix metalloproteinase expression in human macrophages by orthopaedic particulate debris in vitro. Journal of Bone and Joint Surgery B 1998 80 4 694 700 2-s2.0-0031828443 10.1302/0301-620X.80B4.8374
91. Laquerriere P., Grandjean-Laquerriere A., Addadi-Rebbah S., Jallot E., Laurent-Maquin D., Frayssinet P., Guenounou M., MMP-2, MMP-9 and their inhibitors TIMP-2 and TIMP-1 production by human monocytes in vitro in the presence of different forms of hydroxyapatite particles. Biomaterials 2004 25 13 2515 2524 2-s2.0-0742272497 10.1016/j.biomaterials.2003.09.034
92. Ikeda T., Kasai M., Utsuyama M., Hirokawa K., Determination of three isoforms of the receptor activator of nuclear factor- B ligand and their differential expression in bone and thymus. Endocrinology 2001 142 4 1419 1426 2-s2.0-0035054126 10.1210/en.142.4.1419
93. Boyle W. J., Simonet W. S., Lacey D. L., Osteoclast differentiation and activation. Nature 2003 423 6937 337 342 2-s2.0-0037673945 10.1038/nature01658
94. Schwarz E. M., Lu A. P., Goater J. J., Benz E. B., Kollias G., Rosier R. N., Puzas J. E., O'Keefe R. J., Tumor necrosis factor- α /nuclear transcription factor- B signaling in periprosthetic osteolysis. Journal of Orthopaedic Research 2000 18 3 472 480 2-s2.0-0034190257
95. Clohisy J. C., Hirayama T., Frazier E., Han S.-K., Abu-Amer Y., NF-kB signaling blockade abolishes implant particle-induced osteoclastogenesis. Journal of Orthopaedic Research 2004 22 1 13 20 2-s2.0-0345768819 10.1016/S0736-0266(03)00156-6
96. Ren W., Li X. H., Chen B. D., Wooley P. H., Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NF- B activity. Journal of Orthopaedic Research 2004 22 1 21 29 2-s2.0-0345768813 10.1016/S0736-0266(03)00130-X
97. Lamoureux F., Moriceau G., Picarda G., Rousseau J., Trichet V., Rédini F., Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochimica et Biophysica Acta 2010 1805 1 17 24 2-s2.0-75349090418 10.1016/j.bbcan.2009.08.004
98. Ulrich-Vinther M., Carmody E. E., Goater J. J., Soøballe K., O'Keefe R. J., Schwarz E. M., Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. Journal of Bone and Joint Surgery A 2002 84 8 1405 1412 2-s2.0-0036704231
99. Jeffrey Goater J., O'Keefe R. J., Rosier R. N., Edward Puzas J., Schwarz E. M., Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. Journal of Orthopaedic Research 2002 20 2 169 173 2-s2.0-0036124068 10.1016/S0736-0266(01)00083-3
100. Childs L. M., Paschalis E. P., Xing L., Dougall W. C., Anderson D., Boskey A. L., Puzas J. E., Rosier R. N., O'Keefe R. J., Boyce B. F., Schwarz E. M., In vivo RANK signaling blockade using the receptor activator of NF- B:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. Journal of Bone and Mineral Research 2002 17 2 192 199 2-s2.0-0036155498
101. Masui T., Sakano S., Hasegawa Y., Warashina H., Ishiguro N., Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. Biomaterials 2005 26 14 1695 1702 2-s2.0-9644302956 10.1016/j.biomaterials.2004.05.017
102. Mandelin J., Li T.-F., Liljeström M., Kroon M. E., Hanemaaijer R., Santavirta S., Konttinen Y. T., Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. Journal of Bone and Joint Surgery B 2003 85 8 1196 1201 2-s2.0-0344466635 10.1302/0301-620X.85B8.13311
103. Gehrke T., Sers C., Morawietz L., Fernahl G., Neidel J., Frommelt L., Krenn V., Receptor activator of nuclear factor B ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. Scandinavian Journal of Rheumatology 2003 32 5 287 294 2-s2.0-0344010230 10.1080/03009740310003929
104. Haynes D. R., Crotti T. N., Potter A. E., Loric M., Atkins G. J., Howie D. W., Findlay D. M., The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. Journal of Bone and Joint Surgery B 2001 83 6 902 911 2-s2.0-0034859058
105. Horiki M., Nakase T., Myoui A., Sugano N., Nishii T., Tomita T., Miyaji T., Yoshikawa H., Localization of RANKL in osteolytic tissue around a loosened joint prosthesis. Journal of Bone and Mineral Metabolism 2004 22 4 346 351 2-s2.0-3242787387
106. Mandelin J., Li T.-F., Hukkanen M., Liljeström M., Salo J., Santavirta S., Konttinen Y. T., Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor- B ligand, osteoprotegerin, and cathepsin K. Journal of Rheumatology 2005 32 4 713 720 2-s2.0-17144380821
107. Labropoulou V. T., Theocharis A. D., Symeonidis A., Skandalis S. S., Karamanos N. K., Kalofonos H. P., Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions. Current Medicinal Chemistry 2011 18 11 1584 1598 2-s2.0-79955679103 10.2174/092986711795471275
108. Ishibashi O., Niwa S., Kadoyama K., Inui T., MMP-9 antisense oligodeoxynucleotide exerts an inhibitory effect on osteoclastic bone resorption by suppressing cell migration. Life Sciences 2006 79 17 1657 1660 2-s2.0-33748416303 10.1016/j.lfs.2006.05.024
109. Duivenvoorden W. C. M., Hirte H. W., Singh G., Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Invasion and Metastasis 1997 17 6 312 322 2-s2.0-0031545846
110. Franco G. C. N., Kajiya M., Nakanishi T., Ohta K., Rosalen P. L., Groppo F. C., Ernst C. W. O., Boyesen J. L., Bartlett J. D., Stashenko P., Taubman M. A., Kawai T., Inhibition of matrix metalloproteinase-9 activity by doxycycline ameliorates RANK ligand-induced osteoclast differentiation in vitro and in vivo. Experimental Cell Research 2011 317 10 1454 1464 2-s2.0-79955951008 10.1016/j.yexcr.2011.03.014
111. Blavier L., Delaissé J. M., Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. Journal of Cell Science 1995 108 12 3649 3659 2-s2.0-0029616246
112. Engsig M. T., Chen Q.-J., Vu T. H., Pedersen A.-C., Therkidsen B., Lund L. R., Henriksen K., Lenhard T., Foged N. T., Werb Z., Delaisse J.-M., Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. Journal of Cell Biology 2000 151 4 879 889 2-s2.0-0034645060 10.1083/jcb.151.4.879
113. Lynch C. C., Hikosaka A., Acuff H. B., Martin M. D., Kawai N., Singh R. K., Vargo-Gogola T. C., Begtrup J. L., Peterson T. E., Fingleton B., Shirai T., Matrisian L. M., Futakuchi M., MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005 7 5 485 496 2-s2.0-21144438505 10.1016/j.ccr.2005.04.013
114. Wilson T. J., Nannuru K. C., Futakuchi M., Sadanandam A., Singh R. K., Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor- B ligand. Cancer Research 2008 68 14 5803 5811 2-s2.0-48649097728 10.1158/0008-5472.CAN-07-5889
115. Thiolloy S., Halpern J., Holt G. E., Schwartz H. S., Mundy G. R., Matrisian L. M., Lynch C. C., Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. Cancer Research 2009 69 16 6747 6755 2-s2.0-69249094919 10.1158/0008-5472.CAN-08-3949
116. Standal T., Seidel C., Hjertner Ø., Plesner T., Sanderson R. D., Waage A., Borset M., Sundan A., Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002 100 8 3002 3007 2-s2.0-0037108435 10.1182/blood-2002-04-1190
117. Simonet W. S., Lacey D. L., Dunstan C. R., Kelley M., Chang M.-S., Lüthy R., Nguyen H. Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.-L., Trall G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T. M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W. J., Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89 2 309 319 2-s2.0-0031005576
118. Manon-Jensen T., Itoh Y., Couchman J. R., Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS Journal 2010 277 19 3876 3889 2-s2.0-77956646126 10.1111/j.1742-4658.2010.07798.x
119. Li Q., Park P. W., Wilson C. L., Parks W. C., Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002 111 5 635 646 2-s2.0-18744383614 10.1016/S0092-8674(02)01079-6
120. Brule S., Charnaux N., Sutton A., Ledoux D., Chaigneau T., Saffar L., Gattegno L., The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 2006 16 6 488 501 2-s2.0-33646863047 10.1093/glycob/cwj098
121. Fears C. Y., Gladson C. L., Woods A., Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. The Journal of Biological Chemistry 2006 281 21 14533 14536 2-s2.0-33744951974 10.1074/jbc.C600075200
122. Endo K., Takino T., Miyamori H., Kinsen H., Yoshizaki T., Furukawa M., Sato H., Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. The Journal of Biological Chemistry 2003 278 42 40764 40770 2-s2.0-0142103466 10.1074/jbc.M306736200
123. Vermes C., Roebuck K. A., Chandrasekaran R., Dobai J. G., Jacobs J. J., Glant T. T., Particulate wear debris activates protein tyrosine kinases and nuclear factor B, which down-regulates type I collagen synthesis in human osteoblasts. Journal of Bone and Mineral Research 2000 15 9 1756 1765 2-s2.0-0033840505
124. Luo L., Petit A., Antoniou J., Zukor D. J., Huk O. L., Liu R. C. W., Winnik F. M., Mwale F., Effect of cobalt and chromium ions on MMP-1, TIMP-1, and TNF- α gene expression in human U937 macrophages: a role for tyrosine kinases. Biomaterials 2005 26 28 5587 5593 2-s2.0-18144429832 10.1016/j.biomaterials.2005.02.013
125. Yan G.-R., Xiao C.-L., He G.-W., Yin X.-F., Chen N.-P., Cao Y., He Q.-Y., Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways. Proteomics 2010 10 5 976 986 2-s2.0-77649151829 10.1002/pmic.200900662
126. Stahtea X. N., Kousidou O. C., Roussidis A. E., Tzanakakis G. N., Karamanos N. K., Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors. Connective Tissue Research 2008 49 3-4 211 214 2-s2.0-48649095593 10.1080/03008200802143307
127. Ravindranath M. H., Muthugounder S., Presser N., Viswanathan S., Anticancer therapeutic potential of soy isoflavone, genistein. Advances in Experimental Medicine and Biology 2004 546 121 165 2-s2.0-12144255588
128. Goodsell D. S., The molecular perspective: VEGF and angiogenesis. Oncologist 2002 7 6 569 570 2-s2.0-0036914046 10.1634/theoncologist.7-6-569
129. Harry L. E., Paleolog E. M., From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. Birth Defects Research C 2003 69 4 363 374 2-s2.0-0346655231 10.1002/bdrc.10024
130. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.-H., Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. The Journal of Biological Chemistry 1994 269 43 26988 26995 2-s2.0-0027997863
131. Kunstfeld R., Hirakawa S., Hong Y.-K., Schacht V., Lange-Asschenfeldt B., Velasco P., Lin C., Fiebiger E., Wei X., Wu Y., Hicklin D., Bohlen P., Detmar M., Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. Blood 2004 104 4 1048 1057 2-s2.0-3843120939 10.1182/blood-2003-08-2964
132. Nakagawa M., Kaneda T., Arakawa T., Morita S., Sato T., Yomada T., Hanada K., Kumegawa M., Hakeda Y., Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Letters 2000 473 2 161 164 2-s2.0-0034640211 10.1016/S0014-5793(00)01520-9
133. Henriksen K., Karsdal M., Delaissé J.-M., Engsig M. T., RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. The Journal of Biological Chemistry 2003 278 49 48745 48753 2-s2.0-1542782290 10.1074/jbc.M309193200
134. Al-Saffar N., Mah J. T. L., Kadoya Y., Revell P. A., Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants. Annals of the Rheumatic Diseases 1995 54 3 201 208 2-s2.0-0028967582
135. Wang J. Y., Wicklund B. H., Gustilo R. B., Tsukayama D. T., Titanium, chromium and cobalt ions modulate the release of bone-associated cytokines by human monocytes/macrophages in vitro. Biomaterials 1996 17 23 2233 2240 2-s2.0-0030560643 10.1016/0142-9612(96)00072-5
136. Niki Y., Matsumoto H., Suda Y., Otani T., Fujikawa K., Toyama Y., Hisamori N., Nozue A., Metal ions induce bone-resorbing cytokine production through the redox pathway in synoviocytes and bone marrow macrophages. Biomaterials 2003 24 8 1447 1457 2-s2.0-0037376508 10.1016/S0142-9612(02)00531-8
137. Langholz O., Röckel D., Mauch C., Kozlowska E., Bank I., Krieg T., Eckes B., Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by α 1 β 1 and α 2 β 1 integrins. Journal of Cell Biology 1995 131 6 1903 1915 2-s2.0-0029585289 10.1083/jcb.131.6.1903
138. Ravanti L., Heino J., López-Otín C., Kaharin V. M., Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. The Journal of Biological Chemistry 1999 274 2446 2455
139. Tamaki Y., Takakubo Y., Goto K., Hirayama T., Sasaki K., Konttinen Y. T., Goodman S. B., Takagi M., Increased expression of toll-like receptors in aseptic loose periprosthetic tissues and septic synovial membranes around total hip implants. Journal of Rheumatology 2009 36 3 598 608 2-s2.0-65649109779 10.3899/jrheum.080390
140. Gebbia J. A., Coleman J. L., Benach J. L., Selective induction of matrix metalloproteinases by Borrelia burgdorferi via Toll-like receptor 2 in monocytes. Journal of Infectious Diseases 2004 189 1 113 119 2-s2.0-1642457335 10.1086/380414
141. Lisboa R. A., Andrade M. V., Cunha-Melo J. R., Toll-like receptor activation and mechanical force stimulation promote the secretion of matrix metalloproteinases 1, 3 and 10 of human periodontal fibroblasts via p38, JNK and NF-kB. Archives of Oral Biology 2013 58 6 731 739
142. Malik M. H. A., Jury F., Bayat A., Ollier W. E. R., Kay P. R., Genetic susceptibility to total hip arthroplasty failure: a preliminary study on the influence of matrix metalloproteinase 1, interleukin 6 polymorphisms and vitamin D receptor. Annals of the Rheumatic Diseases 2007 66 8 1116 1120 2-s2.0-34547233141 10.1136/ard.2006.062018
143. Ye S., Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biology 2000 19 7 623 629 2-s2.0-0033742833 10.1016/S0945-053X(00)00102-5
144. Benbow U., Rutter J. L., Lowrey C. H., Brinckerhoff C. E., Transcriptional repression of the human collagenase-1 (MMP-1) gene in MDA231 breast cancer cells by all-trans-retinoic acid requires distal regions of the promoter. British Journal of Cancer 1999 79 2 221 228 2-s2.0-0032920196
145. Bramhall S. R., Rosemurgy A., Brown P. D., Bowry C., Buckles J. A. C., Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. Journal of Clinical Oncology 2001 19 15 3447 3455 2-s2.0-0035424135
146. Ortiz-Lazareno P. C., Hernandez-Flores G., Dominguez-Rodriguez J. R., Lerma-Diaz J. M., Jave-Suarez L. F., Aguilar-Lemarroy A., Gomez-Contreras P. C., Scott-Algara D., Bravo-Cuellar A., MG132 proteasome inhibitor modulates proinflammatory cytokines production and expression of their receptors in U937 cells: involvement of nuclear factor- B and activator protein-1. Immunology 2008 124 4 534 541 2-s2.0-46949096956 10.1111/j.1365-2567.2008.02806.x
147. Mao X., Pan X., Cheng T., Zhang X., Inhibition of titanium particle-induced inflammation by the proteasome inhibitor bortezomib in murine macrophage-like RAW 264.7 cells. Inflammation 2012 35 4 1411 1418 2-s2.0-80053351696 10.1007/s10753-011-9392-7
148. Krakauer T., Molecular therapeutic targets in inflammation: cyclooxygenase and NF- B. Current Drug Targets 2004 3 3 317 324 2-s2.0-4444263810 10.2174/1568010043343714
149. Goffin L., Seguin-Estévez Q., Alvarez M., Reith W., Chizzolini C., Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts. Arthritis Research and Therapy 2010 12 2, article 73 2-s2.0-77951554549 10.1186/ar2991
150. Smallie T., Ricchetti G., Horwood N. J., Feldmann M., Clark A. R., Williams L. M., IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. The Journal of Experimental Medicine 2010 207 10 2081 2088 2-s2.0-77957726025 10.1084/jem.20100414
151. Lentsch A. B., Shanley T. P., Sarma V., Ward P. A., In vivo suppression of NF- B and preservation of I B α by interleukin- 10 and interleukin-13. The Journal of Clinical Investigation 1997 100 10 2443 2448 2-s2.0-0030781140
152. Giuliani N., Morandi F., Tagliaferri S., Lazzaretti M., Bonomini S., Crugnola M., Mancini C., Martella E., Ferrari L., Tabilio A., Rizzoli V., The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007 110 1 334 338 2-s2.0-34347400592 10.1182/blood-2006-11-059188
153. Terpos E., Heath D. J., Rahemtulla A., Zervas K., Chantry A., Anagnostopoulos A., Pouli A., Katodritou E., Verrou E., Vervessou E.-C., Dimopoulos M.-A., Croucher P. I., Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor- B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. British Journal of Haematology 2006 135 5 688 692 2-s2.0-33750566914 10.1111/j.1365-2141.2006.06356.x
154. von Metzler I., Krebbel H., Hecht M., Manz R. A., Fleissner C., Mieth M., Kaiser M., Jakob C., Sterz J., Kleeberg L., Heider U., Sezer O., Bortezomib inhibits human osteoclastogenesis. Leukemia 2007 21 9 2025 2034 2-s2.0-34548133601 10.1038/sj.leu.2404806
155. Palombella V. J., Rando O. J., Goldberg A. L., Maniatis T., The ubiquitin-proteasome pathway is required for processing the NF- B1 precursor protein and the activation of NF- B. Cell 1994 78 5 773 785 2-s2.0-0027980321 10.1016/S0092-8674(94)90482-0
156. Reinstein E., Ciechanover A., Narrative review: potein degradation and human diseases: the ubiquitin connection. Annals of Internal Medicine 2006 145 9 676 684 2-s2.0-33750946999
157. Skandalis S. S., Aletras A. J., Gialeli C., Theocharis A. D., Afratis N., Tzanakakis G. N., Karamanos N. K., Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules. Current Molecular Medicine 2012 12 1068 1082
158. Wang M. L., Hauschka P. V., Tuan R. S., Steinbeck M. J., Exposure to particles stimulates superoxide production by human THP-1 macrophages and A vian HD-11EM osteoclasts activated by tumor necrosis factor- α and PMA. Journal of Arthroplasty 2002 17 3 335 346 2-s2.0-0036220309 10.1054/arth.2002. 30416
159. Wu H.-M., Chi K.-H., Lin W.-W., Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. FEBS Letters 2002 526 1-3 101 105 2-s2.0-0037189946 10.1016/S0014-5793(02)03151-4
160. Catalgol B., Ziaja I., Breusing N., Jung T., Höhn A., Alpertunga B., Schroeder P., Chondrogianni N., Gonos E. S., Petropoulos I., Friguet B., Klotz L.-O., Krutman J., Grune T., The proteasome is an integral part of solar ultraviolet a radiation-induced gene expression. The Journal of Biological Chemistry 2009 284 44 30076 30086 2-s2.0-71049176929 10.1074/jbc.M109.044503
161. Fineschi S., Reith W., Guerne P. A., Dayer J.-M., Chizzolini C., Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. FASEB Journal 2006 20 3 562 564 2-s2.0-33645805628 10.1096/fj.05-4870fje
162. Kim H.-J., Barajas B., Wang M., Nel A. E., Nrf2 activation by sulforaphane restores the age-related decrease of TH1 immunity: role of dendritic cells. Journal of Allergy and Clinical Immunology 2008 121 5 1255 1261 2-s2.0-42749088621 10.1016/j.jaci.2008.01.016
163. Sepp-Lorenzino L., Ma Z., Lebwohl D. E., Vinitsky A., Rosen N., Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. The Journal of Biological Chemistry 1995 270 28 16580 16587 2-s2.0-0029008487 10.1074/jbc.270.28.16580
164. Markel D. C., Zhang R., Shi T., Hawkins M., Ren W., Inhibitory effects of erythromycin on wear debris-induced VEGF/Flt-1 gene production and osteolysis. Inflammation Research 2009 58 413 421 2-s2.0-61349143103 10.1007/s00011-009- 0007-9
165. Millett P. J., Allen M. J., Bostrom M. P. G., Effects of alendronate on particle-induced osteolysis in a rat model. Journal of Bone and Joint Surgery A 2002 84 2 236 249 2-s2.0-0036481537
166. von Knoch M., Wedemeyer C., Pingsmann A., Von Knoch F., Hilken G., Sprecher C., Henschke F., Barden B., Löer F., The decrease of particle-induced osteolysis after a single dose of bisphosphonate. Biomaterials 2005 26 14 1803 1808 2-s2.0-9644266509 10.1016/j.biomaterials.2004.06.010
167. Dedes P. G., Gialeli C., Tsonis A., Kanakis I., Theocharis A. D., Kletsas D., Tzanakakis G. N., Karamanos N. K., Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochimica et Biophysica Acta 2012 1820 1926 1939
168. Ito A., Nose T., Takahashi S., Mori Y., Cyclooxygenase inhibitors augment the production of pro-matrix metalloproteinase 9 (progelatinase B) in rabbit articular chondrocytes. FEBS Letters 1995 360 1 75 79 2-s2.0-0028859244 10.1016/0014-5793(95)00085-N
169. DiBattista J. A., Martel-Pelletier J., Fujimoto N., Obata K., Zafarullah M., Pelletier J.-P., Prostaglandins E2 and E1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts: mediation by cyclic-AMP signalling pathway. Laboratory Investigation 1994 71 2 270 278 2-s2.0-0028169833
170. Takahashi S., Inoue T., Higaki M., Mizushima Y., Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts. Inflammation Research 1997 46 8 320 323 2-s2.0-0030815631 10.1007/s000110050194
171. Lin S. K., Wang C. C., Huang S., Lee J. J., Chiang C. P., Lan W. H., Hong C. Y., Induction of dental pulp fibroblast matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 gene expression by interleukin-1alpha and tumor necrosis factor-alpha through a prostaglandin-dependent pathway. Journal of Endodontics 2001 27 3 185 189 2-s2.0-0035292355
172. Yamazaki R., Kawai S., Mizushima Y., Matsuzaki T., Hashimoto S., Yokokura T., Ito A., A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin- 1/proMMP-3 by human rheumatoid synovial cells. Inflammation Research 2000 49 3 133 138 2-s2.0-0034075070
173. Akimoto H., Yamazaki R., Hashimoto S., Sato T., Ito A., 4′-Hydroxy aceclofenac suppresses the interleukin-1-induced production of promatrix metalloproteinases and release of sulfated-glycosaminoglycans from rabbit articular chondrocytes. European Journal of Pharmacology 2000 401 3 429 436 2-s2.0-0034637288 10.1016/S0014-2999(00)00472-6
174. Syggelos S. A., Giannopoulou E., Gouvousis P. A., Andonopoulos A. P., Aletras A. J., Panagiotopoulos E., In vitro effects of non-steroidal anti-inflammatory drugs on cytokine, prostanoid and matrix metalloproteinase production by interface membranes from loose hip or knee endoprostheses. Osteoarthritis and Cartilage 2007 15 5 531 542 2-s2.0-34247555973 10.1016/j.joca.2006.11.003
175. Ishimi Y., Miyaura C., Jin C. H., Akatsu T., Abe E., Nakamura Y., Yamaguchi A., Yoshiki S., Matsuda T., Hirano T., Kishimoto T., Suda T., IL-6 is produced by osteoblasts and induces bone resorption. Journal of Immunology 1990 145 10 3297 3303 2-s2.0-0025259989
176. Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G. D., IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. Journal of Immunology 1990 144 11 4226 4230 2-s2.0-0025313227
177. Lerner U. H., Ohlin A., Tumor necrosis factors α and β can stimulate bone resorption in cultured mouse calvariae by a prostaglandin- independent mechanism. Journal of Bone and Mineral Research 1993 8 2 147 155 2-s2.0-0027512024
178. Herman J. H., Sowder W. G., Hess E. V., Nonsteroidal antiinflammatory drug modulation of prosthesis pseudomembrane induced bone resorption. Journal of Rheumatology 1994 21 2 338 343 2-s2.0-0028300236